Oncology Department, Hopital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.
Université de Paris, Paris, France.
Oncoimmunology. 2021 Feb 17;10(1):1888488. doi: 10.1080/2162402X.2021.1888488.
This review details the clinical utility of Immunoscore, measuring the immune response to cancer within the tumor microenvironment, in bladder cancer. Immunoscore was recently introduced into ESMO Clinical Practice Guidelines for gastrointestinal cancer and into the WHO classification of the Digestive System Tumors. In muscle-invasive bladder cancer (MIBC), the standard-of-care treatment is neo-adjuvant chemotherapy and cystectomy. However, only 50% of the patients are still alive at 5 years. The degree of histologic response positively correlated with Immunoscore and patients at lower risk of relapse or death were associated with a high-Immunoscore. Immunoscore is also predicting response to neoadjuvant chemotherapy-based treatment in several indications. This paves the way for the use of Immunoscore in clinical practice not only in gastrointestinal tumors but also in bladder cancer, and beyond.
这篇综述详细介绍了免疫评分在膀胱癌中的临床应用，它可以衡量肿瘤微环境中的抗肿瘤免疫反应。免疫评分最近被引入 ESMO 胃肠道肿瘤临床实践指南和世界卫生组织消化系统肿瘤分类。在肌层浸润性膀胱癌（MIBC）中，标准治疗方法是新辅助化疗和膀胱切除术。然而，只有 50%的患者在 5 年内仍然存活。组织学反应程度与免疫评分呈正相关，复发或死亡风险较低的患者与高免疫评分相关。免疫评分也可以预测几种适应证下基于新辅助化疗的治疗反应。这为免疫评分在临床实践中的应用铺平了道路，不仅在胃肠道肿瘤中，而且在膀胱癌及其他领域中。
